LPCN Lipocine

Filed: 13 Nov 20, 8:02am











Pursuant to Section 13 or 15(d) of

The Securities Exchange Act of 1934


Date of Report (Date of Earliest Event Reported):

November 13, 2020





(Exact name of registrant as specified in its charter)


Commission File No. 001-36357


Delaware 99-0370688
(State or other jurisdiction of incorporation) (IRS Employer Identification Number)


675 Arapeen Drive, Suite 202

Salt Lake City, Utah 84108

(Address of principal executive offices) (Zip Code)


Registrant’s telephone number, including area code: (801) 994-7383


Former name or former address, if changed since last report: Not Applicable



Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:


¨Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)


¨Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)


¨Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))


¨Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))


Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR § 230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR § 240.12b-2).


Emerging growth company ¨


If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨


Securities registered pursuant to Section 12(b) of the Act:

Title of each classTrading Symbol(s)Name of each exchange on which registered
Common Stock, par value $0.0001 per shareLPCNThe NASDAQ Stock Market LLC





Item 8.01Other Events


The Company will make virtual oral presentations at the at The Liver Meeting Digital Exerience™, hosted by the American Association for the Study of Liver Diseases (“AASLD”), on November 13-16, 2020. The Company’s materials to be included is filed as Exhibits 99.1.



Item 9.01Financial Statements and Exhibits.


(d)       Exhibits


The following exhibits are filed with this report:


Exhibit No.Description


Presentation titled “LPCN 1144 Treatment Potential Assessment in a High Fat Diet Induced Rabbit Model of Hepatic Fibrosis and NASH”








Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.


Date:November 13, 2020 By:/s/ Mahesh V. Patel
    Mahesh V. Patel
    President and Chief Executive Officer